US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,480.06

+12.920.88%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,487.39

Open:1,467.14

Low:1,462.61

Close:1,467.14

Loading ...

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial

MT Newswires Live

BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59

Pfizer: European Commission to Review Chmp Recommendation and Is Expected to Make Final Decision in Coming Months

THOMSON REUTERS

Pfizer’s Abrysvo Gets Positive Chmp Opinion for Adults Aged 18 to 59

THOMSON REUTERS

U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund

Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire

Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps

Is AstraZeneca PLC (AZN) the Best Weight Loss Drug Stock to Buy According to Analysts?

Is BioNTech SE (BNTX) The Best Immunology Stock To Buy Now?

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)

Pfizer (NYSE:PFE) Has A Pretty Healthy Balance Sheet

Simply Wall St.

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.

3 Dividend Stocks That Are No-Brainer Buys Right Now

3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account

Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1480.0557,"timestamp":1741381199999,"preClose":1467.1393,"halted":0,"volume":126573383,"delay":0,"changeRate":0.008804,"change":12.916382,"pbRate":4.037358,"amount":7265241469.443725,"amplitude":0.016884,"prevYearClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"turnoverRate":0.008184,"marketCap":1220494102080,"floatMarketCap":1198623322288,"peRate":31.999995},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1487.3851,"amplitude":0.016884,"preClose":1467.1393,"low":1462.6143,"pbRate":"4.037358","latestPrice":1480.0557,"volume":126573383,"delay":0,"open":1467.1393,"prevYearClose":1274.8187,"prevWeekClose":1463.5875,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1463.5875,"twentyDayClose":1359.8558,"sixtyDayClose":1300.6962,"secType":"PLATE","market":"US","turnoverRate":0.008184,"peRate":31.999995,"marketCap":1220494102080,"floatMarketCap":1198623322288,"timestamp":1741381199999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516112639","title":"Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2516112639","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516112639?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:00","pubTimestamp":1741010400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., March 03, 2025  -- Ocugen, Inc.  , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the European Commission has provided a positive opinion from the European Medicines Agency’s  Committee for Advanced Therapies  for OCU410 and OCU410ST Advanced Therapy Medicinal Product  classification. OCU410 is a novel, multifunctional modifier gene therapy candidate being developed for the treatment of patients with vision loss due to geographic atrophy —an advanced stage of dry age-related macular degeneration —and OCU410ST is being developed for Stargardt disease due to ABCA4-related retinopathies.GA affects 2-3 million people in the United States  and Europe combined. There are two approved therapies in the U.S. that require frequent dosing , however neither therapy has been approved in Europe. Stargardt disease affects 100,000 people in the U.S. and Europe combined, and there are no approved treatments available globally.6-month data ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-announces-positive-opinion-ema-140000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","LU2106854487.HKD","BK4585","MAA","IE00B19Z4B17.USD","IE00B7SZL793.SGD","LU2264538146.SGD","LU0868494708.USD","LU0868494617.USD","LU1974910355.USD","BK4520","BK4157","BK4516","LU2023250504.SGD","BK4588","OCGN","IE00BSNM7G36.USD","BK4149","ATMP","LU1064131342.USD","BK4215","LU0942090050.USD","IE0031619046.USD","LU1988902786.USD","BK4563","BK4597","BK4139","IE00B66KJ199.SGD","BK4532","BK4568","LU2237438978.USD","IE00BD6J9T35.USD","LU1917777945.USD","CAT"],"gpt_icon":0},{"id":"2516180687","title":"Astrazeneca-Amgen Asthma Treatment Reduces Nasal Polyps, Surgery Rates in Phase III Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2516180687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516180687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:59","pubTimestamp":1741003188,"startTime":"0","endTime":"0","summary":"Astrazeneca  said Saturday the full results from the Phase III trial showed Tezspire or tezepelumab, an asthma treatment jointly developed with Amgen , led to significant reductions in nasal polyp severity, surgery requirements, and systemic corticosteroid use for patients with chronic rhinosinusitis with nasal polyps, compared with placebo.At week 52, Tezspire improved the co-primary endpoints, reducing Nasal Polyp Score by -2.065 and nasal congestion by -1.028 compared with placebo, with benefits observed as early as weeks four and two respectively.These findings were published in the New England Journal of Medicine and presented at the American Academy of Allergy Asthma & Immunology and World Allergy Organization Joint Congress in San Diego, California on Saturday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","BK4599","BK4139","BK4566","AMGN","LU1983299246.USD","LU1829250122.USD","BK4534","LU0889565916.HKD","BK4533","BK4588","LU1057294990.SGD","AZN","III","LU1061106388.HKD","LU2242652126.USD","LU1023059063.AUD","BK4585","LU2417539215.USD","LU2456880835.USD","BK4134","LU0109394709.USD","LU0058720904.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","BK4007","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1571399168.USD","LU2236285917.USD","SG9999001440.SGD","LU0320765992.SGD","LU0122379950.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","BK4568","IE0009355771.USD","LU2462157665.USD","LU0289739699.SGD","BK4581","IE0002141913.USD"],"gpt_icon":0},{"id":"2516683029","title":"BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683029","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683029?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:43","pubTimestamp":1740994996,"startTime":"0","endTime":"0","summary":"BRIEF-Pfizer's Abrysvo Gets Positive CHMP Opinion For Adults Aged 18 To 59March 3  - Pfizer Inc PFE.N:PFIZER’S ABRYSVO GETS POSITIVE CHMP OPINION FOR ADULTS AGED 18 TO 59PFIZER: EUROPEAN COMMISSION TO REVIEW CHMP RECOMMENDATION AND IS EXPECTED TO MAKE FINAL DECISION IN COMING MONTHSFurther company coverage: PFE.N ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0170899867.USD","BK4588","LU1894683264.USD","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4533","LU0456855351.SGD","LU0225284248.USD","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0321505439.SGD","SG9999001176.SGD","BK4592","IE0002270589.USD","LU1066051498.USD","LU1894683348.USD","SG9999002232.USD","SG9999003800.SGD","BK4007","BK4585","LU1057294990.SGD","LU0225771236.USD","LU0321505868.SGD","PFE","BK4599","BK4534","SG9999013999.USD","BK4568","IE00B19Z3B42.SGD","LU0868494617.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0985481810.HKD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","SG9999001176.USD","IE000M9KFDE8.USD","BK4581"],"gpt_icon":0},{"id":"2516868394","title":"Pfizer: European Commission to Review Chmp Recommendation and Is Expected to Make Final Decision in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2516868394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516868394?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:32","pubTimestamp":1740994338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0122379950.USD","SG9999003800.SGD","LU0985481810.HKD","LU0170899867.USD","SG9999013999.USD","LU0306807586.USD","LU1894683264.USD","LU0306806265.USD","LU1883839398.USD","BK4585","IE0002270589.USD","BK4550","SG9999001176.SGD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU1894683348.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE00BBT3K403.USD","LU0225284248.USD","BK4534","IE00BLSP4452.SGD","LU0321505868.SGD","LU1066053197.SGD","PFE","BK4581","SG9999011175.SGD","LU1023059063.AUD","LU0058720904.USD","SG9999001176.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4533","BK4599","BK4007","LU0321505439.SGD","SG9999002232.USD","LU0289739699.SGD","BK4568","BK4592","LU1066051498.USD","LU0868494617.USD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2516683916","title":"Pfizer’s Abrysvo Gets Positive Chmp Opinion for Adults Aged 18 to 59","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683916?lang=en_us&edition=fundamental","pubTime":"2025-03-03 17:32","pubTimestamp":1740994338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","SG9999003800.SGD","IE000M9KFDE8.USD","LU1883839398.USD","LU0306807586.USD","LU0225284248.USD","BK4599","LU1057294990.SGD","LU0225771236.USD","LU1066053197.SGD","BK4533","LU1894683348.USD","BK4581","IE00B19Z3581.USD","IE00BLSP4452.SGD","IE00BBT3K403.USD","SG9999002224.SGD","LU0170899867.USD","LU0456855351.SGD","BK4588","SG9999001176.USD","BK4585","BK4007","LU0985481810.HKD","SG9999002232.USD","LU1023059063.AUD","BK4534","LU1894683264.USD","BK4592","BK4568","LU0289739699.SGD","LU1066051498.USD","SGXZ57979304.SGD","PFE","LU0122379950.USD","LU0321505868.SGD","SG9999001176.SGD","LU0306806265.USD","SG9999013999.USD","SG9999011175.SGD","IE0002270589.USD","LU0058720904.USD","IE00BLSP4239.USD","BK4550","IE00B19Z3B42.SGD","LU0234572021.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2516150651","title":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2516150651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516150651?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:43","pubTimestamp":1740987813,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund March 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM0FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0054578231.USD","IE00B19Z9Z06.USD","ASTH","LU2065731478.USD","BK4578","LU0345774631.USD","GEV","ARDT","LU0289739699.SGD","BK4185","GILD","HUBB","LU2087621335.USD","MSDL","LU0724618433.USD","WTS","UHS","LU1721428933.USD","IE00BZ9MQY76.HKD","BK4568","CABO","IE00BN0W2W23.USD","LU1066051498.USD","LU2125910336.SGD","PUBM","LU2298064838.USD","BK4131","ADSK","FDX","LU1992135399.USD","BK4088","BLD","LU0323240290.USD","LU2265009873.SGD","BK4096","FSS","FOXF","LU2326559502.SGD","IE00B66KJ199.SGD","PRAX","GTLS","BJ","VTR","IE00B2PGVK34.USD","IE00B3T34201.USD","LU0889565916.HKD","DCBO","LU1978683503.SGD","LU0251142724.SGD"],"gpt_icon":1},{"id":"2516517473","title":"Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire","url":"https://stock-news.laohu8.com/highlight/detail?id=2516517473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516517473?lang=en_us&edition=fundamental","pubTime":"2025-03-02 22:10","pubTimestamp":1740924616,"startTime":"0","endTime":"0","summary":"Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE significantly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-results-from-phase-3-waypoint-trial-on-tezspire?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amgen-astrazeneca-announce-results-from-phase-3-waypoint-trial-on-tezspire?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00B2B36J28.USD","LU2112291526.USD","BK4568","LU2462157665.USD","LU0320765992.SGD","BK4139","IE00BJT1NW94.SGD","BK4585","BK4599","IE0002141913.USD","LU1061106388.HKD","AZN","AMGN","LU1057294990.SGD","LU2456880835.USD","LU0109394709.USD","LU0889565916.HKD","BK4566","LU1829250122.USD","LU2242652126.USD","LU0122379950.USD","LU1983299246.USD","LU0868494617.USD","BK4581","BK4534","IE0009355771.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","BK4588","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1571399168.USD","IE00B4R5TH58.HKD","LU2417539215.USD","LU2236285917.USD","LU0289739699.SGD","LU1023059063.AUD","SG9999001440.SGD","BK4533"],"gpt_icon":0},{"id":"2516168564","title":"Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps","url":"https://stock-news.laohu8.com/highlight/detail?id=2516168564","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516168564?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:30","pubTimestamp":1740868200,"startTime":"0","endTime":"0","summary":"TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps. WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI/WAO 2025. WILMINGTON, Del., March 01, 2025----Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE  significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps  compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology /World Allergy Organization  Joint Congress in San Diego, CA.1,2. Statistically significant and clinically meaningful improvements were observed across all key secondary outcomes assessed in the overall tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-tezspire-phase-iii-223000077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014484.SGD","BK4585","SG9999002414.USD","SG9999002604.SGD","LU2417539215.USD","LU1829250122.USD","LU2236285917.USD","LU0516422952.EUR","LU0979878070.USD","LU0516423091.SGD","LU2456880835.USD","AZN","LU0516422366.SGD","SG9999001135.SGD","TSS","BK4551","III","SGXZ58947870.SGD","IE0034224299.USD","LU1242518931.SGD","SG9999002406.SGD","LU0516423174.USD","LU0516422440.USD","SG9999002620.SGD","SG9999004360.SGD","BK4568","BK4554","BK4503","LU0889565916.HKD","LU0251143029.SGD","LU0320765992.SGD","SG9999013486.USD","LU0261945553.USD","SG9999014492.USD","FL","BK4134","LU0737861269.HKD","SG9999006266.SGD","LU1242518857.USD","SG9999013478.USD","SG9999013460.SGD","SG9999002679.SGD","BK4566","LU0572939691.SGD","TSLP","LU0532188223.SGD","LU2045819591.USD","BK4535","LU0048573645.USD"],"gpt_icon":1},{"id":"2516934566","title":"Is AstraZeneca PLC (AZN) the Best Weight Loss Drug Stock to Buy According to Analysts?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516934566","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516934566?lang=en_us&edition=fundamental","pubTime":"2025-03-02 03:55","pubTimestamp":1740858925,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where AstraZeneca PLC  stands against other best weight loss drug stocks to buy according to analysts.Global Surge in Obesity Medication Market Driven by GLP-1 Drugs. Morgan Stanley Research has increased its prediction for the global market for obesity medications from $77 billion to $105 billion by 2030 in light of this demand increase. In 2023, brand-name obesity drugs brought in almost $6 billion.According to JP Morgan Research, obesity and diabetes will drive the GLP-1 market’s growth to $100 billion by 2030. By that year, there may be 30 million GLP-1 users in the US or around 9% of the total population. Increased demand for obesity medications will benefit some industries, such as biotech, while posing problems for others, such as the food and beverage sector.The latest generation of GLP-1 medications are being hailed by some as “miracle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-plc-azn-best-weight-195525180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0158827781.USD","LU2357305700.SGD","TSYW.SI","LU2271345857.HKD","LU1162221912.USD","LU0267386448.USD","LU0795875086.SGD","USJW.SI","LU0320765646.SGD","BK4568","LU2456880835.USD","LU2089283258.USD","LU1363072403.SGD","BK4534","LU2023251221.USD","LU0889565916.HKD","NQmain","IE00BZ1G4Q59.USD","LU0106261372.USD","LU1732799900.SGD","QID","LU2133065610.SGD","PSQ","QLD",".IXIC","LU1989772840.SGD","LU2462157665.USD","IE00BKVL7J92.USD","LU1720051108.HKD","LU0158827948.USD","LU1829250122.USD","NVIW.SI","TQQQ","BK4581","LU0225283273.USD","LU0109394709.USD","BK4585","BK4516","LU1548497426.USD","LU2028103732.USD","LU0314104364.USD","LU2089284900.SGD","AZN","MNQmain","LU2417539215.USD","SQQQ","USAW.SI","LU0795875169.SGD","LU1668664300.SGD"],"gpt_icon":1},{"id":"2516356500","title":"Is BioNTech SE (BNTX) The Best Immunology Stock To Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516356500","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516356500?lang=en_us&edition=fundamental","pubTime":"2025-03-02 03:41","pubTimestamp":1740858114,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where BioNTech SE  stands against other best immunology stocks to buy now.Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies. As the global demand for innovative treatments for autoimmune diseases, cancer immunotherapies, and vaccines continues to rise, immunology stocks present lucrative investment opportunities. The market for immunotherapy medications is expected to rise at a high pace, from $240 billion in 2023 to $1.3 trillion in 2033. The rise in chronic illnesses like infections, autoimmune diseases, and various forms of cancer worldwide is what is causing the surge.In 2024, there will likely be more than 2 million new instances of cancer in the US, which will increase demand for efficient therapies like immunotherapy. To provide patients with incurable malignancies like l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biontech-se-bntx-best-immunology-194154813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","USJW.SI","TQQQ","NVIW.SI","BNTX","USAW.SI","BK4139","MNQmain","BK4551","QLD","BK4548","BK4568","NQmain","BK4585","PSQ","TSYW.SI","SQQQ","BK4588","QID",".IXIC"],"gpt_icon":1},{"id":"2516356899","title":"Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX) and Ocugen (OCGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516356899","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516356899?lang=en_us&edition=fundamental","pubTime":"2025-03-02 01:50","pubTimestamp":1740851408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ventyx Biosciences (VTYX – Research Report) and Ocug...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ventyx-biosciences-vtyx-and-ocugen-ocgn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ventyx-biosciences-vtyx-and-ocugen-ocgn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","BK4007","VTYX","BK4568","OCGN","HCSG","BK4563"],"gpt_icon":0},{"id":"2516552661","title":"Pfizer (NYSE:PFE) Has A Pretty Healthy Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2516552661","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516552661?lang=en_us&edition=fundamental","pubTime":"2025-03-01 22:00","pubTimestamp":1740837617,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We can see that Pfizer Inc.  does use debt in its business. But should shareholders be worried about its use of debt?Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. In the worst case scenario, a company can go bankrupt if it cannot pay its creditors. However, a more usual  situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-nyse-pfe-pretty-healthy-140017905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999011175.SGD","LU1894683348.USD","BK4007","BK4534","LU0234572021.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4585","LU1066051498.USD","LU1894683264.USD","LU0058720904.USD","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","BK4533","BK4568","BK4581","LU1057294990.SGD","EBIT","BK4550","NYSE","PFE","SG9999002232.USD","SG9999001176.SGD","LU1023059063.AUD","SG9999001176.USD","LU1066053197.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","SG9999002224.SGD","IE00BLSP4239.USD","BK4588","LU0122379950.USD","IE00BLSP4452.SGD","LU0170899867.USD","LU0225284248.USD","LU0306807586.USD","LU0321505868.SGD","IE0002270589.USD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2516556797","title":"Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2516556797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516556797?lang=en_us&edition=fundamental","pubTime":"2025-03-01 20:53","pubTimestamp":1740833610,"startTime":"0","endTime":"0","summary":"The board of Gilead Sciences, Inc.  has announced that it will be paying its dividend of $0.79 on the 28th of March, an increased payment from last year's comparable dividend. This takes the annual payment to 2.8% of the current stock price, which is about average for the industry.Gilead Sciences' Future Dividend Projections Appear Well Covered By Earnings. We aren't too impressed by dividend yields unless they can be sustained over time. Prior to this announcement, the company was paying out 800% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 38%. Generally, we think cash is more important than accounting measures of profit, so with the cash flows easily covering the dividend, we don't think there is much reason to worry.Analysts expect a massive rise in earnings per share in the next year. Assuming the dividend continues along recent trends, we estimate that the payout ratio could reach 47%, which is in a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaq-gild-increasing-125330339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1839511570.USD","LU0058720904.USD","LU2210150020.SGD","PSQ","BK4578","BK4583","LU2468319806.SGD","BK4568","LU1066053197.SGD","LU0889565916.HKD","NVIW.SI","IE00B19Z3B42.SGD",".IXIC","LU2210149790.SGD","BK4112","IE00BSNM7G36.USD","MNQmain","IE00B3T34201.USD","LU2087621335.USD","IE00B64PRP62.GBP","IE0002270589.USD","QID","BK4588","LU2095319765.USD","IE00B7SZLL34.SGD","QLD","LU0234570918.USD","USJW.SI","IE00BZ1G4Q59.USD","BK4532","TSYW.SI","NDAQ","IE00BGHQF748.EUR","LU0320765992.SGD","LU1066051498.USD","SQQQ","IE00BKPKM429.USD","LU0289739699.SGD","LU0109394709.USD","TQQQ","LU1585245621.USD","IE00B3QW5Z07.USD","GILD","LU1571399168.USD","USAW.SI","BK4585","NQmain","BK4566"],"gpt_icon":1},{"id":"2516755816","title":"3 Dividend Stocks That Are No-Brainer Buys Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2516755816","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516755816?lang=en_us&edition=fundamental","pubTime":"2025-03-01 17:51","pubTimestamp":1740822660,"startTime":"0","endTime":"0","summary":"Investors should look beyond Johnson & Johnson's recent challenges.Novartis offers a high dividend yield that investors can count on.Pfizer's dividend is especially juicy, and its stock is a bargain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/01/3-dividend-stocks-that-are-no-brainer-buys-right/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["PFE","LU1585245621.USD","US3Y.BOND","LU0225284248.USD","US12M.BOND","LU0466842654.USD","IE00B7SZLL34.SGD","LU1032466523.USD","US30Y.BOND","BK4568","BK4007","US5Y.BOND","LU1280957306.USD","JNJ","BK4534","BK4504","SG9999001440.SGD","IE00BJJMRZ35.SGD","LU0306807586.USD","LU2505996681.GBP","LU1066053197.SGD","SG9999002232.USD","US10Y.BOND","IE00B2B36J28.USD","LU1066051225.USD","LU0098860793.USD","IE00BGHQF631.EUR","LU1066051811.HKD","LU1929549753.HKD","LU2602419157.SGD","BK4533","IE000M9KFDE8.USD","US2Y.BOND","IE0034235303.USD","IE00BMG7P694.USD","PEG","LU0640476718.USD","LU2129689431.USD","LU0321505868.SGD","LU0345769631.USD","US6M.BOND","IE00BVYPNV92.GBP","LU0170899867.USD","LU0912757837.SGD","BK4208","IE0002270589.USD","LU1059921491.USD","LU0225771236.USD","IE00BJT1NW94.SGD","US7Y.BOND"],"gpt_icon":1},{"id":"2516530129","title":"3 Top High-Yield Dividend Stocks I Just Bought in My Retirement Account","url":"https://stock-news.laohu8.com/highlight/detail?id=2516530129","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516530129?lang=en_us&edition=fundamental","pubTime":"2025-03-01 17:03","pubTimestamp":1740819780,"startTime":"0","endTime":"0","summary":"Enbridge has increased its high-yielding dividend for 30 years in a row.Invitation Homes has raised its payment every year since coming public.Kenvue has continued the dividend-paying legacy of its former parent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/01/3-top-high-yield-dividend-stocks-i-just-bought-in/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0098860793.USD","LU0345770993.USD","US3Y.BOND","LU1057294990.SGD","LU1059921491.USD","REIT","LU1894683264.USD","US30Y.BOND","US10Y.BOND","US6M.BOND","LU1074936037.SGD","IE00B1BXHZ80.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1032955483.USD","LU1061106388.HKD","LU1732800096.USD","LU1894683348.USD","US5Y.BOND","BK4588","BK4533","LU1244550494.USD","LU1506573853.SGD","LU0320765646.SGD","IE00BVYPNV92.GBP","LU0203345920.USD","BK4568","BK4592","LU0058720904.USD","US7Y.BOND","IE00BVYPNW00.USD","LU2089984988.USD","BK4504","LU0882574055.USD","IE00B19Z3581.USD","LU1430594728.SGD","US12M.BOND","US2Y.BOND","BK4585","IE0034235303.USD","LU1066051811.HKD","LU0889566641.SGD","LU2129689514.USD","SG9999001440.SGD","LU1244550577.SGD","IE000M9KFDE8.USD","LU0912757837.SGD","LU1929549753.HKD","JNJ","LU0345769128.USD"],"gpt_icon":0},{"id":"2516589697","title":"Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2516589697","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516589697?lang=en_us&edition=fundamental","pubTime":"2025-03-01 07:15","pubTimestamp":1740784508,"startTime":"0","endTime":"0","summary":"Astrazeneca  ended the recent trading session at $76.21, demonstrating a +0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.59%. Meanwhile, the Dow gained 1.39%, and the Nasdaq, a tech-heavy index, added 1.63%.Heading into today, shares of the pharmaceutical had gained 6.19% over the past month, outpacing the Medical sector's loss of 0.63% and the S&P 500's loss of 2.42% in that time.Market participants will be closely following the financial results of Astrazeneca in its upcoming release. The company's earnings per share  are projected to be $1.09, reflecting a 5.83% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $13.58 billion, reflecting a 7.07% rise from the equivalent quarter last year.Investors might also notice recent changes to analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. With thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-astrazeneca-azn-gained-231508471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2456880835.USD","BK4588","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK4568","LU2462157665.USD","BK4007","LU0889565916.HKD","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":20,"pageCount":10,"totalSize":313}]}}